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ARTICLE INFO  ABSTRACT 
 
 
The pandemic state, declared by the World Health Organization, on March 11, 2020, has tested 
society's adaptability and response. A race against time to seek strategies to fight the disease of 
the new coronavirus contributes to the union of scientists from all over the world, including using 
nanotechnology Thus, the objective of the study was described the landscape of nanotechnology 
strategies against COVID-19,highlighting mainly the products and diagnostics, vaccines and 
treatments that are or can be used. A literature review was carried out in studies published from 
February to November2020 in PubMed, Scielo, and Google Scholar databases. According to the 
indexes of the various databases, search terms were used: “new coronavirus 2019”, “COVID-19”, 
“severe acute respiratory syndrome” Nanotechnology against COVID-19”, “COVID-19 
Vaccines” without any language restrictions. The use of nano-based materials has indicated a 
great potential against dissemination of COVID-19, with the production of products, diagnostics, 
vaccines and treatments. Our results demonstrate that nanotechnology offers processes, materials 
and tools that contribute to increase the sensitivity, agility and reliability of the diagnostic, in 
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In December 2019, there were the first outbreaks in China due 
to the novel coronavirus (SARS-COV-2). With the growing 
number of cases in several countries, on March 11, 2020, the 
world health organization declared the 2019 coronavirus 
disease pandemic (COVID-19). Since then, scientists from 
different countries share the same goal: to develop treatments, 
vaccines, diagnostics, and products against COVID-19 
(Ahmed et al., 2020; Pacheco et al., 2020). The different 
technological strategies against COVID-19 allowed scientific 
and technological development also in the field of 
nanotechnology, presenting a great need to better understand  
 
 
and explore this novel nano-virus (60-140 nm in diameter) 
(Sportelli et al., 2020; Tabish & Hamblin, 2020; Talebian et 
al., 2020). Nanotechnology provides the development of 
systems under a dimension of fewer than 100 nanometers, with 
potential for both diagnostic, treatment, and prevention of 
diseases, through nanoparticles that have unique properties, 
presenting better solubility, biocompatibility, conductivity, 
reduced toxicity, and multifunctionality (Campos et al., 2020; 
Vazquez-Munoz & Lopez-Ribot, 2020). Nanotechnology 
applied to the medical field is known as nanomedicine, where 
nanomaterials are used for treatments, vaccines, diagnostics, or 
disease prevention products (Choi & Han, 2018).  
ISSN: 2230-9926 
 
International Journal of Development Research 






Received 20th September, 2020 
Received in revised form  
09th October, 2020 
Accepted 14th November, 2020 
Published online 30th December, 2020 
 
Available online at http://www.journalijdr.com 
 
Citation: Thyago José Arruda Pacheco, Franciéle de Matos da Silva, Danielle Galdino de Souza, Victor Carlos Mello da Silva and Raquel Santos Faria. 
“The landscape of nanotechnology strategies against COVID-19: products and diagnostics, vaccines and treatments”, International Journal of Development 
Research, 10, (12), 42526-42531. 
 












*Corresponding author:  
Thyago José Arruda Pacheco 
Nanomedicine, for example, is capable of being used to 
improve immunogenicity with prophylactic approaches. 
Nanoparticles can work basically by increasing the activation 
of immunity so that it protects against disease (Yadav et al., 
2018). Due to their size, 1-100 nm, nanotransporters such as 
liposomes, nanoemulsions, synthetic polymeric nanoparticles, 
proteasomes, nano-granules, inorganic nanomaterials, as well 
as biological polymeric nanoparticles (exosome, 
bacteriophage) have been widely tested and used in the 
prevention of infectious and non-infectious diseases, as they 
can be captured by cells by endocytosis, and thus release 
biologically active compounds (Zaman et al., 2013; Zhao et 
al., 2014). Another important feature of nanotechnology in the 
medical field is the ability to modify the surface and 
effectively co-deliver adjuvants, which makes nanoparticles a 
potential candidate for commercial vaccines. Also, nano 
adjuvants in vaccines protect the target antigen from 
degradation and increase absorption by immunological 
mediators of biological systems. This approach is malleable, 
having the ability to present the antigen in a repetitive manner 
leading to stable immunogenic properties (Vicente et al., 2010; 
Zhao et al., 2014). This type of nanomedicine-based approach 
has already been used against SARS-CoV-1 and MERS and 
now with SARS-COV-2 (Chan, 2020). Nanomedicine has 
been present in the modern world for decades, having its first 
product regulated by the Federal Drug Administration (FDA) 
in 1995 (Flühmann et al., 2019). There are many applications 
of nanomedicine for different uses. Here we highlight mainly 
the products and diagnostics, vaccines and treatments that are 




A literature review was carried out in studies published from 
February to 12th November 2020 in PubMed, Scielo, and 
Google Scholar databases. According to the indexes of the 
various databases, search terms were used: “new coronavirus 
2019”, “COVID-19”, “Nanotechnology against COVID-19”, 
“COVID-19 Vaccines“, “severe acute respiratory syndrome” 
without any language restrictions. Those who described a 
comparative overview of coronavirus, treatments, vaccines, 





Products and diagnostics: During this fight against 
coronavirus 2019 (COVID-19), our main line of defense is our 
immune system; however, people who are 
immunocompromised or who have at least one underlying 
comorbidity are considered to be quite vulnerable and their 
only line of defense is disinfectants, facial masks, immune 
system stimulants and medications (Talebian et al., 2020) (Fig. 
1). The nanotechnology field has grown a lot with these new 
technological advances, and several products based on nano or 
antiviral agents to block SARS-CoV-2 have been developed 
(Abu-Faraj, n.d.; Itani et al., 2020). Antimicrobial and antiviral 
formulations based on nanotechnology can prevent the spread 
of the SARS-CoV-2 virus, and the development of highly 
sensitive biosensors and detection platforms can contribute to 










Figure 2. Vaccines using nanotechnology. 1) Nanometric Virus 
carring “particles” of SARS-COV-2 (RNA or other subunits). 2) 
Nanoparticles carrying “particles” of SARS-COV-2. These 
particles inside of virus or nanoparticles are reponsible for 
stimulating factors (like viral proteins from SARS-COV-2) that 




Figure 3. Nanoparticles inhibiting the effects of viral infections in 
three main ways. (I) blocking receptor binding and entering the 




42527   Thyago José Arruda Pacheco et al., The landscape of nanotechnology strategies against Covid-19: Products and diagnostics, vaccines and treatments 
 
Viral disinfectants, produced using nano-effective 
antimicrobial and antiviral formulations, are suitable for 
disinfecting air and surfaces and are also effective in 
reinforcing personal protective equipment, such as face 
respirators. Metallic nanoparticles (silver, copper, titanium 
dioxide nanoparticles) have been proposed as alternatives due 
to their wide range of inherent antiviral activities, persistence, 
and ability to be effective at much lower doses (Sportelli et al., 
2020). These nanomaterials have enormous potential as 
disinfectants against coronavirus, as they have intrinsic 
antiviral properties, such as the generation of reactive oxygen 
species (ROS) and photodynamic and photothermal 
capabilities. The adverse effects on human health and the 
environment of metallic nanomaterials can be avoided with the 
use of biodegradable (that is polymeric, lipid-based) 
nanomaterials (Talebian et al., 2020). Preliminary tests showed 
that the silver nanocluster coating/silica composite in 
disposable FFP3 face masks (3M TM) had viricidal effects 
against SARS-CoV-2 (Balagna et al., 2020). The Nano Tech 
Surface developed by Italy is a durable and self-sterilizing 
formula composed of titanium dioxide and silver ions to 
disinfect surfaces. Graphene sheets with antibodies have the 
potential to quickly detect targeted viral proteins and are also 
used for the development of environmental sensors and filters, 
due to the low cost of graphene materials.  
 
Functionalized graphene has demonstrated a good capacity for 
viral capture that, combined with heat or light-mediated 
inactivation, can be used as a disinfectant (Palmieri & Papi, 
2020). Reusable and recyclable graphene surgical masks with 
excellent superhydrophobic, photothermal performances, and 
excellent self-cleaning properties are commercially available 
(Zhong et al., 2020). Researchers in Egypt have developed a 
new device against SARS-CoV-2. This corresponds to a 
breathing filter mask design based on polylactic acid (PLA), a 
biodegradable and transparent polymer, cellulose acetate (CA), 
copper oxide nanoparticles (CuONPs), and graphene oxide 
(GO). The objective is to allow the polymeric network to 
prevent the entry of viral particles into the nasal cavity, while 
CuONPs and GO further inhibit the potential for viral 
transmission by inactivating the particles trapped in the 
membrane itself (Ahmed et al., 2020). Viral detection may be 
possible through the development of highly sensitive and 
accurate nanosensors that allow early diagnosis of COVID-19. 
Nanomaterials functionalized with nucleic acids or antibodies 
represent the main lines of detection based on nano, through 
colorimetric or antigen-binding assays, as well as light and 
photothermal platforms (Li et al., 2020). Researchers at the 
Korea Institute of Basic Sciences developed a field-effect 
transistor (FET) -based biosensor device to detect SARS-CoV-
2 in clinical samples. The sensor was produced by coating FET 
graphene sheets with a specific antibody against the SARS-
CoV-2 spike protein. Sensor performance was determined 
using antigen proteins, cultured viruses, and nasopharyngeal 
smear specimens from COVID-19 patients. This device has an 
extraordinary ability to distinguish the SARS-CoV-2 antigen 
protein from those of the MERS-CoV (Seo et al., 2020). 
 
Vaccines: Data from November 12nd show that there are 19 
vaccines, from 212, against COVID-19, being developed and 
that describe in their production method nanomedicine, such as 
lipid nanoparticles, liposomes, or viral particles (DRAFT 
landscape of COVID-19) (Seo et al., 2020). Four of them are 
already under clinical evaluation, three in phase 3 
(Moderna/NIAID, Novavax and BioNTech/Fosun 
Pharma/Pfizer) and the one from Imperial College London in 
phase 1, the latter has not yet released its results so far (Table 
1). All of these in the clinical phase use lipid nanoparticles 
encapsulating RNA encoding structures of the new 
coronavirus (Draft Landscape of COVID-19 Candidate 
Vaccines, n.d.) (Fig. 2). The potential vaccine in phase 3, 
RNA-1273, manufactured by Moderna TX Inc, is an mRNA-
based vaccine encapsulated by lipid nanoparticles, which is 
capable of encoding the Spike (S) protein of the SARS-CoV-2 
virus in the host cell. Since this RNA is encapsulated by lipid 
nanoparticles, the vaccine can be injected intramuscularly into 
patients. So, when injected, it takes the mRNA to host immune 
cells encoding the spike protein, so these cells make copies of 
the protein as if the cells have been infected by the coronavirus 
and then other immune cells can interact with these spike 
proteins and trigger the cascade effect of the immune system, 
leaving the individual protected against possible infection by 
the coronavirus. This technology took just 42 days to develop 
and induced anti-SARS-CoV-2 immune responses in all 
participants, with no limiting safety concerns identified in the 
trial (Jackson et al., 2020). 
 
The other potential vaccine with phase 3 nanotechnology is 
BNT162b1, manufactured by BioNTech / Fosun Pharma / 
Pfizer. This is a nucleoside-modified mRNA vaccine, also 
formulated with lipid nanoparticles that encode the trimerized 
receptor (RBD) binding domain of the SARS-CoV-2 virus 
spike glycoprotein. The first results of BNT162b1 were 
published by Nature. Different doses were administered, with 
an acceptable tolerability and safety profile. The researchers 
are very optimistic for a rapid production of a vaccine against 
SARS-CoV-2 to prevent COVID- 19 (Mulligan et al., 2020). 
Finally, the third potential vaccine against COVID-19 in phase 
3 using nanotechnology is produced by Novavax (NVX-
CoV2373). This vaccine utilizes immunogenic virus-like 
nanoparticles based on recombinant expression of the S-
protein. The results from phase 1-2 trial were detailed in the 
New England Journal of Medicine. The NVX-CoV2373 
showed good results. being safe and triggered immune 
responses that exceeded levels in Covid-19 convalescent 
serum (Keech et al., 2020). 
 
Treatments: Several nanobiotechnological platforms were 
able to combat human viruses, and preclinical studies, such as 
herpes, hepatitis B, HIV, in addition to some respiratory 
viruses (Jackman et al., 2016; Patel et al., 2017). These 
platforms can be used to develop therapies and diagnoses 
against SARS-CoV-2 or other future pandemics (Amanat & 
Krammer, 2020; Chan, 2020; Weiss et al., 2020). When 
analyzing the panorama of the therapeutic development of 
COVID-19 with other diseases, we can see that, in both cases, 
the most important thing is to align the correct drug with the 
most promising nanocarrier (Chauhan et al., 2020). Thus, we 
can infer that the challenges for the development of therapies 
against COVID-19, as well as for other viral diseases or even 
cancer, for example, are very similar. However, in general 
aspects, the encounter of the virus with the susceptible host is 
what makes viral infection possible. We can divide four 
especially important points of the relationship between viruses 
and host cells for the maintenance of the infectious process. 
First - the adsorption and penetration of the viral agent in the 
host; second - transcription, translation (synthesis) and 
maturation of the viable progeny; third - the release of the 
host's progeny; and fourth - the resistance of the viral agent to 
the adversities of the environment (Kostarelos, 2020).  
 









































According to that, we can also observe that therapeutic drugs 
based on NP can inhibit the effects of viral infections in three 
main ways (I) blocking receptor binding and entering the cell, 
(II) inhibiting viral infection, and (III) viral inactivation. (I) 
Blocking the binding to the receptor and entering the cell, as 
shown in the work by Huang et al, where the AuNRs 
nanoparticle blocked the entry of the MERS virus AgNPs 
showed efficient antiviral activity against RSV (herpes 
simplex virus) infection by directly inactivating the virus 
before entering host cells(Huang et al., 2019). Silica 
nanoparticles (SiNPs) can act as efficient eliminators of the 
human immunodeficiency virus (HIV) and the respiratory 
syncytial virus (RSV) (Souza et al., 2016). (II) The inhibition 
of viral infection, as shown in the study by Lin and coauthors 
(2017), Se @ ZNV (selenium nanoparticles with the antiviral 
zanamivir) revealed good biological activity to contain the 
proliferation of the influenza virus H1N1 (Osminkina et al., 
2014). According to Souza et al. (2016) SiO NPs were able to 
inhibit HIV infection, showing that the use of these 
functionalized silica particles presented a promising approach 
for the control of HIV infection and viral control (Souza et al., 
2016). (III) Viral inactivation, as presented in the study by 
Ghaffari et al., (2019) the PEGylated ZnO-NPs nanoparticles 
had an antiviral activity with inhibitory properties against the 
H1N1 influenza virus. Kong et al. (2019) observed that 








































even suggesting nanodisks as therapeutic agents against 
enveloped viruses (Fig. 3) Despite the treatment options 
currently proposed, the number of serious cases and deaths of 
patients infected with SARS-CoV-2 is still high. Much of the 
side effects of antivirals are caused by their accumulation in 
off-target organs. Nanoparticles can optimize drug delivery to 
target infection sites and with controlled release properties 
(Chhikara et al., 2020). Therefore, we must also focus on 
alternative approaches, such as nanotechnology, to achieve an 
effective treatment for this disease and to minimize the side 




There are several options for products, treatments, and 
vaccines nano-based against COVID-19. The great hope is 
placed on vaccines and three of them, in phase 3, use 
nanotechnology. Nanomedicine has already demonstrated its 
ability to protect, diagnose, and treat other viral diseases or 
infections; therefore, it may also have a great capacity to fight 
COVID-19. One of the biggest challenges is ensuring the safe 
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Table 1. Description of vaccines based on nanoparticles against COVID-19 (On November 2020) 
 
Nome Organizações envolvidas Método da vacina Fase 
Moderna/NIAID National Institutes of Health (NIH) and 
Moderna (United States) 
LNP (lipid nanoparticles) -encapsulated 
mRNA 
Fase 1 NCT04283461 
Fase 2 NCT04405076 
Fase 3 NCT04470427 
Novavax Novavax, Inc. (United States) Full length recombinant SARS CoV-2 
glycoprotein nanoparticle vaccine adjuvanted 
with Matrix M  
Fase ½ NCT04368988 
Fase 2b NCT04533399 
Fase 3 2020-004123-16 
NCT04611802 
Ad5-nCoV CanSino Biological Inc./Beijing Institute of 
Biotechnology (China) 
Adenovirus vector 5, containing SARS-CoV-
2 S nanoparticles 
Fase 1 ChiCTR2000030906 
NCT04568811 
Fase 2 ChiCTR2000031781 
NCT04566770 
Fase 3 NCT04526990 
NCT04540419 
BNT162 (a1, b1, b2, c2) BioNTech/Fosun Pharma/Pfizer/ 
(United States / Germany) 
LNP-encapsulated mRNA Fase 1 NCT04368728 
Fase ½ 2020-001038-36 
ChiCTR2000034825 
NCT04537949 
Fase 3 NCT04368728 
LNP-nCoVsaRNA Imperial College London (England) LNP encapsulated self-amplifying RNA 
(saRNA) 
Fase 1 ISRCTN17072692 
Vaccine candidate Max-Planck-Institute of Colloids and 
Interfaces (Germany) 
LNP-encapsulated mRNA encoding the 
receptor binding domain (RBD) of protein 
SARS-CoV-2 
Pre-Clinical 
Vaccine candidate Bio/Sanofi Pasteur (France) LNP-encapsulated mRNA Pre-Clinical 
Vaccine candidate CanSino Biologics / Precision NanoSystems 
(China / Canada) 
LNP-encapsulated mRNA Pre-Clinical 
Vaccine candidate Fudan University/ Shanghai JiaoTong 
University/RNACure Biopharma (China) 
LNP-encapsulated mRNA encoding RBD of 
protein S SARS-CoV-2 
Pre-Clinical 
Vaccine candidate Fudan University/ Shanghai JiaoTong 
University/RNACure Biopharma (China) 
LNP-encapsulated mRNA cocktail encoding 
VLP  
Pre-Clinical 
Vaccine candidate University of Tokyo/ Daiichi-Sankyo 
(Japan) 
LNP-encapsulated mRNA Pre-Clinical 
Vaccine candidate BIOCAD (Russia) Liposome-encapsulated mRNA  Pre-Clinical 
Vaccine candidate Chula Vaccine Research Center/University 
of Pennsylvania (United States) 
LNP-encapsulated mRNA Pre-Clinical 
Vaccine candidate National institute of Chemistry (Slovenia) Plasmid DNA, nanostructured RBD  Pre-Clinical 
Vaccine candidate Ohio State University / Kazakh National 
Agrarian University (United States/ Kazakh) 
RBD protein delivered in mannoseconjugated 
chitosan nanoparticle 
Pre-Clinical 
Vaccine candidate Saint-Petersburg scientific research institute 
of vaccines and serums (Russia) 
Recombinant protein, nanoparticles (based on 
S-protein and other epitopes) 
Pre-Clinical 
Vaccine candidate LakePharma, Inc (United States) Nanoparticle vaccine Pre-Clinical 
Vaccine candidate IMV Inc (Canada) Peptide antigens formulated in LNP Pre-Clinical 
Vaccine candidate Globe Biotech Ltd (Bangladesh) D614G variant LNP-encapsulated mRNA  Pre-Clinical 
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Scientific Development (CNPq), Coordinating Agency for 
Advanced Training of Graduate Personnel (CAPES), 
Foundation for Research Support of the Federal District 
(FAPDF) an the Dean of Research and Post-Graduation of the 
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